BeOne Medicines (BEIGF) Construction in Progress (2016 - 2026)

BeOne Medicines (BEIGF) has reported Construction in Progress for 10 consecutive years, with $152.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Construction in Progress fell 56.83% year-over-year to $152.7 million in Q2 2026; TTM through Jun 2026 was $152.7 million, a 56.83% decrease from a year earlier, with the FY2025 full-year figure at $127.2 million, down 80.56% from the prior year.
• Construction in Progress was $152.7 million for Q2 2026 at BeOne Medicines, up from $137.4 million in the prior quarter.
• Over five years, Construction in Progress peaked at $863.4 million in Q2 2024 and troughed at $127.2 million in Q4 2025.
• A 5-year average of $430.5 million and a median of $376.9 million in 2023 frame the typical range for Construction in Progress.
• Across the five-year window, Construction in Progress soared 184.02% in 2023 and plunged 80.56% in 2025, its largest moves.
• Over 5 years, Construction in Progress stood at $293.6 million in 2022, then soared by 152.23% to $740.6 million in 2023, then declined by 11.69% to $654.0 million in 2024, then sank by 80.56% to $127.2 million in 2025, then gained by 20.06% to $152.7 million in 2026.
• The last three Construction in Progress figures came in at $152.7 million (Q2 2026), $137.4 million (Q1 2026), and $127.2 million (Q4 2025), per Business Quant data.